摘要
目的 探讨长链非编码RNA-02870(LINC02870)对肝细胞性肝癌(HCC)细胞(PLC细胞)增殖的影响及机制。方法 常规培养PLC细胞并随机分为对照组、过表达组,分别转染载体对照pcDNA3.1+质粒、LINC02870质粒,48 h后常规进行细胞传代。采用实时定量聚合酶链式反应检测细胞内LINC02870表达,用CCK8实验、EdU染色法检测细胞增殖能力,用Western blotting法检测细胞内磷酸化真核细胞起始因子4E结合蛋白1(p-4EBP-1)表达。结果 对照组、过表达组LINC02870相对表达量分别为1.00±0.07、113.40±1.57,两组比较差异有统计学意义(P<0.05)。培养24、48、72 h,过表达组OD值逐渐升高,且均高于对照组同期(P均<0.05);过表达组EdU染色阳性细胞比例高于对照组(P<0.05)。过表达组p-4EBP-1蛋白相对表达量高于对照组(P均<0.05)。结论 LINC02870可促进HCC细胞增殖,其机制可能与调控4EBP-1蛋白磷酸化有关。
Objective To investigate the effect of the long non-coding RNA 02870(LINC02870) on the proliferation of hepatocellular carcinoma(HCC) cells and its mechanism.Methods PLC cells were routinely cultured and randomly divided into the control group and the overexpression group,which were transfected with the vector control pcDNA3.1+plasmid and LINC02870 plasmid,respectively.After 48 h,the routine cell passage was carried out.Real-time quantitative PCR was used to detect the expression of LINC02870 in cells,CCK8 and EdU assay were used to detect the cell proliferation ability,and Western blotting was used to detect the expression of phosphorylated eukaryotic translation initiation factor 4 E-binding protein 1(p-4 EBP-1) in cells.Results The relative expression of LINC02870 was 1.00±0.07 in the control group and 113.40±1.57 in the overexpression group,and the difference between the two groups was statistically significant(P<0.05).After 24,48 and 72 h of culture,the OD450 values of the overexpression group gradually increased,which were higher than those of the control group in the same period(all P<0.05).The proportion of EdUstained positive cells in the overexpression group was higher than that in the control group(P<0.05).The relative expression of p-4 EBP-1 protein in the overexpression group was higher than that in the control group(P<0.05).Conclusion LINC02870 promotes the proliferation of HCC cells,and the mechanism may be related to the regulation of phosphorylation level of 4 EBP-1 protein.
作者
郭梦雅
邵晓雯
黄佳宁
白楠
李茗鹤
李咏梅
GUO Mengya;SHAO Xiaowen;HUANG Jianing;BAI Nan;LI Minghe;LI Yongmei(Basic Medicine College,Tianjin Medical University,Tianjin 300070,China;不详)
出处
《山东医药》
CAS
2022年第31期48-51,共4页
Shandong Medical Journal
基金
国家自然科学基金面上项目(81872377)。
作者简介
通信作者:李咏梅,E-mail:liym@tmu.edu.cn。
